Kronox Lab Sciences Limited announces an acquisition

The stated rationale is to obtain substantial ownership and sole control of Kronox Lab Sciences to expand its operations. The acquirer also describes the transaction as part of a long-term portfolio-diversification strategy focused on sectors with stability and growth potential, with the intention of supporting management and employees, expanding the business, and creating value for stakeholders. ^[1]

On governance, the Draft Letter of Offer does not state a specific plan to nominate directors or replace management policy. It records that neither the acquirer nor its directors currently sit on Kronox’s board and that no director has been nominated as of the draft date. ^[2] However, the acquirer explicitly intends to acquire and exercise sole control over Kronox, becoming its promoter while Zenrock becomes part of the promoter group. ^[3]

Interpretation: the disclosed intent is control and operational expansion, not an expressly stated board-representation or management-policy overhaul. Nevertheless, “sole control” gives the acquirer the ability to influence governance and strategic decisions post-acquisition, even though a specific board or management action is not set out.

The Open Offer price is Rs 157.27 per share, versus a reported 60-trading-day VWAMP of Rs 2,157.27 per share. Thus, the offer price is Rs 2,000.00 lower, or approximately 92.71% below the VWAMP. ^[4]

The IPO issue price is not stated in the cited Draft Letter of Offer, so a verified comparison with the IPO price cannot be made from this filing.

Cash outflow

Assuming full acceptance:

• Offer shares: 95,70,000, representing 25.79% of voting share capital ^[5]
• Offer price: Rs 157.27 per share ^[5]
• Calculation: 95,70,000 × Rs 157.27
• Maximum cash consideration: Rs 150,50,73,900, or approximately Rs 150.51 Crores ^[6]

This is the cash consideration for the 25.79% open-offer stake only; it excludes the separate consideration for the 64.26% promoter stake acquired under the SPA.

The Draft Letter of Offer schedules the tendering period for 15–29 October 2026, both days inclusive. However, these are indicative dates rather than irrevocably confirmed dates, because the schedule remains subject to applicable statutory or regulatory approvals and may be revised. ^{[7] [8]}

Conditions precedent to completing the purchase

• Current position: The Acquirer and PAC state that, as of the Draft Letter of Offer, they are not aware of any statutory or other approvals required to consummate either the underlying acquisition or the open offer. ^[9]
• Subsequently applicable approvals: If any statutory or other approval becomes applicable before the tendering period closes, the Acquirer and/or PAC must make the necessary applications, and completion of the underlying transaction and open offer will remain subject to receipt of that approval. ^[10]
• SPA conditions precedent: The underlying 64.26% stake purchase is also subject to the other conditions precedent in the Share Purchase Agreement, unless those conditions are waived or deferred in accordance with the SPA. The Draft Letter of Offer extract does not enumerate every such SPA condition. ^{[10] [11]}
• Seller warranties: Completion of the underlying purchase is conditional on the Sellers’ warranties being true and correct in all material respects at completion. ^[11]
• Failure or refusal: If a required approval is finally refused, or an SPA condition is not satisfied for reasons outside the Acquirer’s/PAC’s reasonable control and the SPA is terminated, they may withdraw the open offer under Regulation 23(1). ^[12]

The DLOF itself is not SEBI approval: the final Letter of Offer remains subject to SEBI’s approval, and filing the draft does not remove the obligation to obtain any statutory clearances that may ultimately be required. ^{[13] [14]}